Characteristics of implanted tumors
| Diagnosis . | ID . | Clonal B-cells . | Nonclonal B cells . | Non-B cells . | Viable at thaw . | Engrafted . | Molecular confirmation of clonality . | Monoclonal plasma cell by κ/λ . |
|---|---|---|---|---|---|---|---|---|
| DLBCL | B | 12% | 14% | 64% | + | + | IGKV, IGHV Seq | − |
| G | n.d. | 45% | + | + | t(14;18) | − | ||
| N | 0% | 5% | 95% | + | + | t(14;18) | − | |
| V | n.d. | 91% | + | + | t(14;18) | − | ||
| Follicular | ||||||||
| Grade 1 | ||||||||
| E | >99% | <1% | <1% | + | + | IGKV, IGHV Seq | + | |
| F | 38% | 5% | 57% | + | + | IGKV | − | |
| L | 58% | 13% | 29% | + | + | t(14;18) | − | |
| P | n.d. | + | − | not applicable | − | |||
| S | 71% | 5% | 24% | + | + | t(14:18) | − | |
| Grade 2 | ||||||||
| J | 52% | 13% | 35% | + | + | t(14;18) | − | |
| T | 61% | 12% | 27% | + | + | t(14;18) | − | |
| Grade 3 | ||||||||
| A | 20% | 0% | 80% | + | + | t(14;18) | − | |
| C2 | n.d. | + | + | t(14;18) | − | |||
| Mantle | C1 | 29% | 1% | 70% | + | + | BCL1, IGKV, IGHV Seq | + |
| K | 100% | 0% | 0% | + | − | not applicable | − | |
| Marginal | M | 90% | <1% | 10% | + | + | IGKV, IGHV Seq | + |
| O | n.d. | − | − | not applicable | − | |||
| W | 72% | <1% | 18% | + | + | IGHV Seq | + | |
| A2 | 57% | 3% | 40% | + | + | IGHV Seq | − | |
| B2 | n.d. | + | + | IGHV Seq | − | |||
| Diagnosis . | ID . | Clonal B-cells . | Nonclonal B cells . | Non-B cells . | Viable at thaw . | Engrafted . | Molecular confirmation of clonality . | Monoclonal plasma cell by κ/λ . |
|---|---|---|---|---|---|---|---|---|
| DLBCL | B | 12% | 14% | 64% | + | + | IGKV, IGHV Seq | − |
| G | n.d. | 45% | + | + | t(14;18) | − | ||
| N | 0% | 5% | 95% | + | + | t(14;18) | − | |
| V | n.d. | 91% | + | + | t(14;18) | − | ||
| Follicular | ||||||||
| Grade 1 | ||||||||
| E | >99% | <1% | <1% | + | + | IGKV, IGHV Seq | + | |
| F | 38% | 5% | 57% | + | + | IGKV | − | |
| L | 58% | 13% | 29% | + | + | t(14;18) | − | |
| P | n.d. | + | − | not applicable | − | |||
| S | 71% | 5% | 24% | + | + | t(14:18) | − | |
| Grade 2 | ||||||||
| J | 52% | 13% | 35% | + | + | t(14;18) | − | |
| T | 61% | 12% | 27% | + | + | t(14;18) | − | |
| Grade 3 | ||||||||
| A | 20% | 0% | 80% | + | + | t(14;18) | − | |
| C2 | n.d. | + | + | t(14;18) | − | |||
| Mantle | C1 | 29% | 1% | 70% | + | + | BCL1, IGKV, IGHV Seq | + |
| K | 100% | 0% | 0% | + | − | not applicable | − | |
| Marginal | M | 90% | <1% | 10% | + | + | IGKV, IGHV Seq | + |
| O | n.d. | − | − | not applicable | − | |||
| W | 72% | <1% | 18% | + | + | IGHV Seq | + | |
| A2 | 57% | 3% | 40% | + | + | IGHV Seq | − | |
| B2 | n.d. | + | + | IGHV Seq | − | |||
BCL1, tumor-specific expression of nuclear BCL1 detected by IHC; IGHV, biomed-2 IGHV clonality assay; IGHV Seq: identity established by sequencing of the rearranged IGVH; IGKV, biomed-2 IGKV clonality assay; t(14;18), identity established by primer pair and length of PCR product of the translocation breakpoint; light chain immunohistochemistry: clonality established by light chain restriction in the plasma cell component of the tumor (>10:1).